• In May 2026, Arteris, Inc. announced that its FlexNoC 5 interconnect IP and Magillem SoC integration automation software were deployed by Li Auto Inc. to support AI compute data movement and integration in Li Auto’s proprietary 5 nm SoCs, starting with the L9 Livis smart SUV.
• This client adoption underscores Arteris’ role in enabling high-performance, energy-efficient, safety-focused automotive chips that integrate CPUs, GPUs, AI accelerators, sensors, and functional safety capabilities into increasingly complex smart vehicle platforms.
• We’ll now examine how Arteris’ role in Li Auto’s 5 nm smart vehicle SoCs may influence the company’s investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Arteris Investment Narrative Recap

To own Arteris, you need to believe its system IP can become a go to choice for increasingly complex AI and automotive chips, even as the company remains loss making. The Li Auto 5 nm SoC win reinforces the near term catalyst of growing AI and auto design wins, but does not change the core risk that high operating costs and continued net losses could weigh on the stock if revenue momentum slows.

Among recent developments, the Renesas license for FlexNoC in its Gen 5 R Car automotive SoCs is especially relevant. Together with the Li Auto deployment, it highlights how Arteris is becoming more embedded in safety centric, AI heavy vehicle platforms, which ties directly into the catalyst of expanding automotive design activity while also concentrating exposure to a relatively small set of high value customers.

Yet while wins like Li Auto are encouraging, investors should also be aware that customer concentration risk could...

Arteris' narrative projects $130.9 million revenue and $15.0 million earnings by 2029.

Uncover how Arteris' forecasts yield a $20.50 fair value, a 45% downside to its current price.

Exploring Other Perspectives

The more cautious analysts remind you that even before this Li Auto win, they expected about US$148,000,000 of 2029 revenue and persistent losses, so they see client concentration and global competition very differently.

Explore 5 other fair value estimates on Arteris - why the stock might be worth as much as $20.50!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arteris research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Arteris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arteris' overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.